Story perspectives

Regeneron Signs White House Pricing Deal, Cuts Praluent to $225

4/24/2026

Summary

Story summary

Regeneron became the company to sign the White House’s most-favored-nation drug-pricing agreement.
U.S. President Donald Trump announced Regeneron will lower Medicaid prices and sell Praluent for $225 on TrumpRx.gov.
Regeneron pledged $27 billion for U.S. research, development and manufacturing.
Regeneron’s gene therapy Otarmeni received FDA approval for a rare hearing loss and will be offered free to patients.
Secretary Robert F. Kennedy Jr. said contract details will be released if not proprietary.

History

Historical Context

The Trump administration's 2020 most-favored-nation drug pricing agreement aimed to lower U.S. prescription costs, reflecting a historical trend of rising drug prices and limited negotiation power for Medicare since the 2003 Medicare Part D. This initiative parallels the Affordable Care Act of 2010, which sought to improve medication access, highlighting ongoing debates about drug pricing transparency and affordability in the U.S. healthcare system.

1 of 2

Story summary

Regeneron became the company to sign the White House’s most-favored-nation drug-pricing agreement.
U.S. President Donald Trump announced Regeneron will lower Medicaid prices and sell Praluent for $225 on TrumpRx.gov.
Regeneron pledged $27 billion for U.S. research, development and manufacturing.
Regeneron’s gene therapy Otarmeni received FDA approval for a rare hearing loss and will be offered free to patients.
Secretary Robert F. Kennedy Jr. said contract details will be released if not proprietary.

1 / 2